The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
Open accessAbstract
Background The selective TRK inhibitor larotrectinib was approved for paediatric and adult patients with advanced TRK fusion-positive solid tumours based on a primary analysis set of 55 patients. The aim of our analysis was to explore the efficacy and long-term safety of larotrectinib in a larger population of patients with TRK fusion-positive solid tumours.Methods Patients were enrolled and treated in a phase 1 adult, a phase 1/2 paediatric, or a phase 2 adolescent and adult trial. Some eligibility criteria differed between these studies. For this pooled analysis, eligible patients were aged 1 month or older, with a locally advanced or metastatic non-CNS primary, TRK fusion-positive solid tumour, who had received standard therapy previously if available. This analysis set includes the 55 patients on which approval of larotrectinib was based. Larotrectinib was administered orally (capsule or liquid formulation), on a continuous 28-day schedule, to adults mostly at a dose of 100 mg twice daily, and to paediatric patients mostly at a dose of 100 mg/m 2 (maximum of 100 mg) twice daily. The primary endpoint was objective response as assessed by local investigators in an intention-to-treat analysis. Contributing trials are registered with ClinicalTrials.gov, NCT02122913 (active not recruiting), NCT02637687 (recruiting), and NCT02576431 (recruiting).Findings Between May 1, 2014, and Feb 19, 2019, 159 patients with TRK fusion-positive cancer were enrolled and treated with larotrectinib. Ages ranged from less than 1 month to 84 years. The proportion of patients with an objective response according to investigator assessment was 121 (79%, 95% CI 72-85) of 153 evaluable patients, with 24 (16%) having complete responses. In a safety population of 260 patients treated regardless of TRK fusion status, the most common grade 3 or 4 larotrectinib-related adverse events were increased alanine aminotransferase (eight [3%] of 260 patients), anaemia (six, 2%), and decreased neutrophil count (five [2%]). The most common larotrectinib-related serious adverse events were increased alanine aminotransferase (two [<1%] of 260 patients), increased aspartate aminotransferase (two [<1%]), and nausea (two [<1%]). No treatment-related deaths occurred.Interpretation These data confirm that TRK fusions define a unique molecular subgroup of advanced solid tumours for which larotrectinib is highly active. Safety data indicate that long-term administration of larotrectinib is feasible.Funding Bayer and Loxo Oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Nevertheless, entrectinib and lartotrectinib have demonstrated activity in patients with solid tumors with NTRK fusion”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“In this trial, 8 of 159 patients had colon cancer”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“with a median duration of 3.7 months.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“4 patients with colon cancer had a response to therapy”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“and the FDA has approved their use for these patients.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“Two therapies, larotrectinib and entrectinib, are FDA-approved for use in CRC with NTRK mutation.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“Based on the efficacy across tumor types, larotrectinib was FDA-approved for tumors with NTRK fusions, including CRC.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Self-citationAlectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
NTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. E. D. C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,521
Self-citationSkálová, A., Vaněček, T., Šíma, R., Laco, J., Weinreb, I., Perez‐Ordoñez, B., Stárek, I., Geierová, M., Simpson, R. H., Passador‐Santos, F., et al. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181d9efcc · Cited by 1,017
Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma
Tognon, C. E., Knezevich, S. R., Huntsman, D. D., Roskelley, C. D., Melnyk, N., Mathers, J. A., Becker, L. E., Carneiro, F., Macpherson, N. A., Horsman, D. E., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00180-0 · Cited by 908
Drilon, A. E. D. C., Siena, S., Ou, S. I., Patel, M. R., Ahn, M., Lee, J., Bauer, T. M., Farago, A. F., Wheler, J. J., Liu, S. V., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1237 · Cited by 833
Self-citation
Research works printed but not linked: 1
- Geoerger, 2019, Larotrectinib efficacyand safety in pediatric patients with TRK fusion cancer, Pediatr Blood Cancer, 66, S4
Cited by
Sorted by citations
Items 201–300 of 1,000
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial
Besse, B., Lin, J. J., Bazhenova, L. A., Goto, K., Langen, A. J. D., Kim, D., Wolf, J., Springfeld, C., Popat, S., Lim, W., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04079-7 · Cited by 28
Self-citationHarmonising patient-access programmes: the Dutch DRUG Access Protocol platform
Zeverijn, L. J., van Doorn-Khosrovani, S. B. V. W., van Roy, A. A. M. G. P., Timmers, L., Tran, T. H. L., de Boer, J. E., de Wit, G. F., Geurts, B. S., Gelderblom, H. A. J., Verheul, H. M. W., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00707-5 · Cited by 28
Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer
Carlson, J. J. (2022) · The American Journal of Managed Care · doi:10.37765/ajmc.2022.88845 · Cited by 28
Koopman, B., Kuijpers, C. C. H. J., Groen, H. J. M., Timens, W., Schuuring, E. M. D., Willems, S. M., & van Kempen, L. C. L. T. (2022) · Diagnostics · doi:10.3390/diagnostics12030668 · Cited by 28
Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?
Rémond, M., Pellat, A., Brézault, C., Dhooge, M., & Coriat, R. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100638 · Cited by 28
Lemmon, C. A., Zhou, J. H. S., Hobbs, B. P., & Pennell, N. A. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00294 · Cited by 28
Importance of ROS1 fene fusions in non-small cell lung cancer
Muminovic, M., Uribe, C. R. C., Alvarez-Pinzon, A. M., Shan, K. S., & Raez, L. E. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2022.105 · Cited by 28
Review of Novel Surgical, Radiation, and Systemic Therapies and Clinical Trials in Glioblastoma
Valerius, A. R., Webb, L. M., Thomsen, A., Lehrer, E. J., Breen, W. G., Campian, J. L., Riviere-Cazaux, C., Burns, T. C., & Sener, U. T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910570 · Cited by 27
Delgado, J., Péan, E., Melchiorri, D., Migali, C., Josephson, F., Enzmann, H. G., & Pignatti, F. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100087 · Cited by 27
Stencel, K. M., Chmielewska, I., Milanowski, J., & Ramlau, R. (2021) · Cancers · doi:10.3390/cancers13081829 · Cited by 27
Umemoto, K., Yamamoto, H., Oikawa, R., Takeda, H., Doi, A., Horie, Y., Arai, H., Ogura, T., Mizukami, T., Izawa, N., et al. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac106 · Cited by 27
Current Molecular Profile of Gastrointestinal Stromal Tumors and Systemic Therapeutic Implications
Mathias-Machado, M. C., de Jesus, V. H. F., Oliveira, L. J. D. C., Neumann, M., & Peixoto, R. D. (2022) · Cancers · doi:10.3390/cancers14215330 · Cited by 27
A molecular guide to systemic therapy in salivary gland carcinoma
Weaver, A. N., Lakritz, S., Mandair, D., Ulanja, M. B., & Bowles, D. W. (2023) · Head & Neck · doi:10.1002/hed.27307 · Cited by 27
NTRK fusions in thyroid cancer: Pathology and clinical aspects
Ma, Y., Zhang, Q., Zhang, K., liang, Y., Ren, F., Zhang, J., Kan, C., Han, F., & Sun, X. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103957 · Cited by 27
Small-molecule drugs of colorectal cancer: Current status and future directions
Yang, Y., Liu, P., Zhou, M., Yin, L., Wang, M., Liu, T., Jiang, X., & Gao, H. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166880 · Cited by 27
Kehmann, L., Jördens, M. S., Loosen, S. H., Luedde, T., Roderburg, C., & Leyh, C. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103706 · Cited by 26
Tumor-Agnostic Therapies in Practice: Challenges, Innovations, and Future Perspectives
Wu, S., & Thawani, R. (2025) · Cancers · doi:10.3390/cancers17050801 · Cited by 26
Refractory Metastatic Colorectal Cancer: Current Challenges and Future Prospects
Lam, M., Lum, C., Latham, S., Smith, S. T., Prenen, H., & Segelov, E. (2020) · Cancer Management and Research · doi:10.2147/cmar.s213236 · Cited by 26
Sun, J., Liu, S., Fu, K., Gao, N., Li, R., He, W., & Gao, Z. (2021) · Scientific Reports · doi:10.1038/s41598-021-01970-4 · Cited by 26
Precision medicine in pediatric solid cancers
Blattner-Johnson, M., Jones, D., & Pfaff, E. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.008 · Cited by 26
Tissue-Agnostic Drug Development: A New Path to Drug Approval
Thein, K. Z., Lemery, S. J., & Kummar, S. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0554 · Cited by 26
Self-citationSystemic Therapy for Lung Cancer Brain Metastases
Pellerino, A., Bruno, F., Rudà, R., & Soffietti, R. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00911-7 · Cited by 26
Oncogenic fusions: Targeting NTRK
Hagopian, G. G., & Nagasaka, M. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104234 · Cited by 26
Laetsch, T. W., Voss, S. D., Ludwig, K. F., Hall, D. C., Barkauskas, D. A., DuBois, S. G., Ronan, J., Rudzinski, E. R., Memken, A., Robinson, K., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco-24-01854 · Cited by 26
Self-citationNTRK gene fusion testing and management in lung cancer
Repetto, M., Garassino, M. C., Loong, H. H.-F., López‐Ríos, F., Mok, T. S. K., Peters, S., Planchard, D., Popat, S., Rudzinski, E. R., Drilon, A. E. D. C., et al. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102733 · Cited by 25
Self-citationItaliano, A., Nanda, S., Briggs, A. H., García‐Foncillas, J., Lassen, U., Vassal, G., Kummar, S., van Tilburg, C. M., Hong, D. S., Laetsch, T. W., et al. (2020) · Cancers · doi:10.3390/cancers12113246 · Cited by 25
Self-citationVellichirammal, N. N., Chaturvedi, N. K., Joshi, S. S., Coulter, D. W., & Guda, C. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.015 · Cited by 25
Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology
Rohrberg, K. S., & Lassen, U. (2021) · Drugs · doi:10.1007/s40265-020-01459-w · Cited by 25
Self-citationApplicability of pan-TRK immunohistochemistry for identification of NTRK fusions in lung carcinoma
Strohmeier, S., Brčić, I., Popper, H., Liegl‐Atzwanger, B., Lindenmann, J., & Brčić, L. (2021) · Scientific Reports · doi:10.1038/s41598-021-89373-3 · Cited by 25
Neurologic Complications of Cancer Therapies
Lee, E. Q. (2021) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-021-01151-w · Cited by 25
Yin, L., Shi, C., He, X. Z., Yan, Q., Chen, H., Chen, M., Zhang, Z., Chen, Y., Zhou, Y., & Zhang, H. (2022) · Pathology · doi:10.1016/j.pathol.2022.10.003 · Cited by 25
Multidisciplinary approach and treatment of acral and mucosal melanoma
Fortuna, A., & Amaral, T. M. S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1340408 · Cited by 25
The present and future of precision oncology and tumor-agnostic therapeutic approaches
Shah, N. M., & Meric‐Bernstam, F. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf152 · Cited by 24
Tomlins, S. A., Hovelson, D. H., Harms, P. W., Drewery, S., Falkner, J. A., Fischer, A. K., Hipp, J., Kwiatkowski, K., de la Vega, L. L., Mitchell, K., et al. (2021) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.08.005 · Cited by 24
Freitag, V., Lettmaier, S., Semrau, S., Hecht, M., Mantsopoulos, K., Müller, S. K., Traxdorf, M., Iro, H., Agaimy, A., Fietkau, R., et al. (2021) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-021-07024-9 · Cited by 24
NTRK fusions in colorectal cancer: clinical meaning and future perspective
Ratti, M., Grizzi, G., Passalacqua, R., Lampis, A., Cereatti, F., Grassia, R., & Hahne, J. C. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1978070 · Cited by 24
Schlick, K., Kiem, D., & Greil, R. (2021) · Biomolecules · doi:10.3390/biom11101469 · Cited by 24
The clinical aspect of NTRK-fusions in pediatric papillary thyroid cancer
Ricarte‐Filho, J. C., Halada, S., O’Neill, A., Casado‐Medrano, V., Laetsch, T. W., Franco, A. T., & Bauer, A. J. (2022) · Cancer Genetics · doi:10.1016/j.cancergen.2022.01.002 · Cited by 24
Self-citationInfectious Complications of Targeted Therapies in Children with Leukemias and Lymphomas
Kyriakidis, I., Mantadakis, E., Stiakaki, E., Groll, A. H., & Tragiannidis, A. (2022) · Cancers · doi:10.3390/cancers14205022 · Cited by 24
Iannantuono, G. M., Riondino, S., Sganga, S., Rosenfeld, R., Guerriero, S., Carlucci, M., Capotondi, B., Torino, F., & Roselli, M. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12111819 · Cited by 24
Tropomyosin receptor kinase B ( TrkB ) signalling: targeted therapy in neurogenic tumours
Li, Y., Wei, C., Wang, W., Li, Q., & Wang, Z. (2022) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.307 · Cited by 24
Challenges and Strategies to Combat Resistance Mechanisms in Thyroid Cancer Therapeutics
Gild, M. L., Bullock, M., Tsang, V., Clifton-Bligh, R. J., Robinson, B. G., & Wirth, L. J. (2023) · Thyroid · doi:10.1089/thy.2022.0704 · Cited by 24
Deyell, R. J., Shen, Y., Titmuss, E., Dixon, K., Williamson, L. M., Pleasance, E., Nelson, J., Abbasi, S., Krzywinski, M. I., Armstrong, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48363-5 · Cited by 24
Chu, X., Bu, Y., & Yang, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.785855 · Cited by 24
Novel Therapeutics in Soft Tissue Sarcoma
Mavroeidis, L., Napolitano, A., Huang, P. H., & Jones, R. L. (2024) · Cancers · doi:10.3390/cancers17010010 · Cited by 23
Pancreatic cancer in 2025: Have we found a solution?
Tonini, V., & Zanni, M. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i43.111433 · Cited by 23
Ciardiello, D., Maiorano, B. A., Parente, P., Rodriquenz, M. G., Latiano, T. P., Chiarazzo, C., Pazienza, V., Guerrera, L. P., Amoruso, B., Normanno, N., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020820 · Cited by 23
New approaches for patients with advanced radioiodine-refractory thyroid cancer
Pitoia, F., Jerkovich, F., Trimboli, P., & Smulever, A. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i1.9 · Cited by 23
Iannantuono, G. M., Torino, F., Rosenfeld, R., Guerriero, S., Carlucci, M., Sganga, S., Capotondi, B., Riondino, S., & Roselli, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158535 · Cited by 23
The Role of Neural Signaling in the Pancreatic Cancer Microenvironment
Takahashi, R., Ijichi, H., & Fujishiro, M. (2022) · Cancers · doi:10.3390/cancers14174269 · Cited by 23
New developments in targeted therapy for metastatic colorectal cancer
Wong, A. H. N., Ma, B. B. Y., & Lui, R. N.-S. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221148540 · Cited by 23
Dufresne, A., Pissaloux, D., Duong-Ngo, C., Penel, N., Cesne, A. L., Macagno, N., Vanacker, H., Henon, C., Jean‐Denis, M., Rughoo, K., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101202 · Cited by 23
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types
Schubert, L., Elliott, A., Le, A. T., Estrada‐Bernal, A., Doebele, R. C., Lou, E., Borghaei, H., Demeure, M. J., Kurzrock, R., Reuss, J. E., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1115405 · Cited by 23
Regua, A. T., Bindal, S., Najjar, M. K., Zhuang, C., Khan, M. S., Arrigo, A., Gonzalez, A. O., Zhang, X. R., Zhu, J., Watabe, K., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217023 · Cited by 23
Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy
Lubitz, C. C., Sadow, P. M., Daniels, G. H., & Wirth, L. J. (2021) · Thyroid · doi:10.1089/thy.2020.0962 · Cited by 23
Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards
Fujiwara, Y., Kato, S., & Kurzrock, R. (2026) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2026.05.019 · Cited by 22
Molecular Landscape and Therapeutic Strategies in Pediatric Differentiated Thyroid Carcinoma
Yang, A. T., Lai, S.-T. T., Laetsch, T. W., Bhatti, T. R., Baloch, Z. W., Surrey, L. F., Franco, A. T., Ricarte‐Filho, J. C., Mostoufi‐Moab, S., Adzick, N. S., et al. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf003 · Cited by 22
Self-citationGuidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment
Serrano, C., Bauer, S., Blay, J., Casali, P. G., Cicala, C. M., Tos, A. P. D., Digklia, A., Gelderblom, H. A. J., Italiano, A., Jones, R. L., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.3608 · Cited by 22
Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours
Garrido, P., Hladun, R., de Álava, E., Alvarez, R. M., Bautista, F. J., López‐Ríos, F., Colomer, R., & Rojo, F. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02558-0 · Cited by 22
Building a precision medicine infrastructure at a national level: The Swedish experience
Edsjö, A., Lindstrand, A., Gisselsson, D., Mölling, P., Friedman, M., Cavelier, L. B., Johansson, M., Ehrencrona, H., Fagerqvist, T., Strid, T., et al. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.3 · Cited by 22
Wisinski, K. B., Flamand, Y., Wilson, M. A., Luke, J. J., Tawbi, H. A., Hong, F., Mitchell, E. P., Zwiebel, J. A., Chen, H., Gray, R. J., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00421 · Cited by 22
Precision Oncology in Gastrointestinal Stromal Tumors
Mechahougui, H., Montemurro, M., & Friedlaender, A. (2023) · Current Oncology · doi:10.3390/curroncol30050351 · Cited by 22
Targeted therapies in non-small cell lung cancer: present and future
McLaughlin, J., Berkman, J. D., & Nana-Sinkam, P. S. (2023) · Faculty Reviews · doi:10.12703/r/12-22 · Cited by 22
Roth, J. A., Carlson, J. J., Xia, F., Williamson, T. E., & Sullivan, S. D. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.20045 · Cited by 22
Oncology drug-companion diagnostic combinations
Jørgensen, J. T. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100492 · Cited by 22
Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma
König, D., Hench, J., Frank, S., Dima, L., Hench, I. B., & Laubli, H. P. (2022) · Pharmacology · doi:10.1159/000524399 · Cited by 22
Hibar, D. P., Demetri, G. D., Peters, S., Davies, J., Humblet, O., Maund, S. L., & Pérez, L. M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0270571 · Cited by 22
Tumour-agnostic kinase inhibitors
Adashek, J. J., Nikanjam, M., & Kurzrock, R. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01147-y · Cited by 21
Impact of tissue-agnostic approvals for patients with sarcoma
Pestana, R. C., Beal, J. R., Parkes, A. M., Hamerschlak, N., & Subbiah, V. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.11.007 · Cited by 21
Systematic population-based identification of NTRK and RET fusion-positive thyroid cancers
Eszlinger, M., Stewardson, P., McIntyre, J. B., Box, A. H., Khalil, M., Hyrcza, M. D., Koro, K., Ruether, D., Wu, J., & Paschke, R. (2022) · European Thyroid Journal · doi:10.1530/etj-21-0061 · Cited by 21
EML4–NTRK3 Fusion Cervical Sarcoma: A Case Report and Literature Review
Dang, X., Xiang, T., Zhao, C. H., Tang, H., & Cui, P. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.832376 · Cited by 21
Wagner, V. P., Ferrarotto, R., Vargas, P. A., Martins, M. D., Bingle, C. D., & Bingle, L. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103886 · Cited by 21
Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma
Brandt, A. P., Thiele, B., Schultheiß, C., Daetwyler, E., & Binder, M. (2023) · Cancers · doi:10.3390/cancers15072051 · Cited by 21
Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer
Leone, G. M., Candido, S., Lavoro, A., Vivarelli, S., Gattuso, G., Călina, D. C., Libra, M., & Falzone, L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041252 · Cited by 21
Orbach, D. H., Carton, M., Khadir, S. K., Feuilly, M., Kurtinecz, M., Phil, D., Vokuhl, C., Kościelniak, E., Pierron, G., Lemelle, L., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103006 · Cited by 21
NTRK gene fusions: a rough diamond ready to sparkle
Rolfo, C. D. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30026-7 · Cited by 21
Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer
Nokin, M., Ambrogio, C., Nadal, E., & Santamaría, D. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.11.005 · Cited by 21
Precision Medicine for Childhood Cancer: Current Limitations and Future Perspectives
McCabe, M. G., Geoerger, B., Chesler, L., Hargrave, D. R., Parsons, D. W., van Tilburg, C. M., Schleiermacher, G., Hickman, J. A., & George, S. L. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00117 · Cited by 21
Self-citationEfficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer
Hong, D. S., Xu, R., Shen, L., Dierselhuis, M. P., Orbach, D. H., McDermott, R., Italiano, A., Tahara, M., Bernard-Gauthier, V., Neu, N., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105110 · Cited by 20
Self-citationDynamic interplay of neuroendocrine signaling and immuno-surveillance in tumor niche remodeling
Xu, N., Bian, S., Lyu, P., He, X., & Zheng, W. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104958 · Cited by 20
Prisciandaro, M., Antista, M., Raimondi, A., Corti, F., Morano, F., Centonze, G., Sabella, G., Mangogna, A., Randon, G., Pagani, F., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.780716 · Cited by 20
Histologic characterization of paediatric mesenchymal neoplasms treated with kinase‐targeted therapy
Baranov, E., Winsnes, K., O’Brien, M. J., Voss, S. D., Church, A. J., Janeway, K. A., DuBois, S. G., Davis, J. L., & Al‐Ibraheemi, A. (2022) · Histopathology · doi:10.1111/his.14680 · Cited by 20
Self-citationBiology-guided precision medicine in rare cancers: Lessons from sarcomas and neuroendocrine tumours
van der Graaf, W. T. A., Tesselaar, M. E. T., McVeigh, T. P., Oyen, W. J. G., & Fröhling, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.05.011 · Cited by 20
Tarawneh, T. S., Rodepeter, F. R., Teply‐Szymanski, J., Ross, P., Koch, V., Thölken, C., Schäfer, J., Gremke, N., Mack, H. I. D., Gold, J., et al. (2022) · Cancers · doi:10.3390/cancers14184430 · Cited by 20
Nero, C., Duranti, S., Giacomini, F., Minucci, A., Giacò, L., Piermattei, A., Genuardi, M., Pasciuto, T., Urbani, A., Daniele, G., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12101746 · Cited by 20
NTRK fusions in solid tumours: what every pathologist needs to know
Nguyen, M. A., Colebatch, A. J., Beek, D. V., Tierney, G., Gupta, R., & Cooper, W. A. (2023) · Pathology · doi:10.1016/j.pathol.2023.05.002 · Cited by 20
Immune Cells in the Tumor Microenvironment of Soft Tissue Sarcomas
Jumaniyazova, E. D., Lokhonina, А. V., Dzhalilova, D. S., Kosyreva, A. M., & Fatkhudinov, T. (2023) · Cancers · doi:10.3390/cancers15245760 · Cited by 20
New systemic treatment options for advanced cholangiocarcinoma
Zanuso, V., Tesini, G., Valenzi, E., & Rimassa, L. (2024) · Journal of Liver Cancer · doi:10.17998/jlc.2024.08.07 · Cited by 20
Cytomorphologic features of NTRK‐rearranged thyroid carcinoma
Viswanathan, K., Chu, Y., Faquin, W. C., & Sadow, P. M. (2020) · Cancer Cytopathology · doi:10.1002/cncy.22374 · Cited by 20
Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?
Weis, L. N., Tolaney, S. M., Barrios, C. H., & Barroso‐Sousa, R. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00328-3 · Cited by 20
Lefler, D. S., Tierno, M. B., & Bashir, B. (2022) · Cancer Biology & Therapy · doi:10.1080/15384047.2022.2029128 · Cited by 20
Bertaglia, V., Morelli, A. M., Solinas, C., Aiello, M. M., Manunta, S., Denaro, N., Tampellini, M., Scartozzi, M., & Novello, S. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103954 · Cited by 20
Mauro, A. D., Berretta, M., Santorsola, M., Ferrara, G., Picone, C., Savarese, G., & Ottaiano, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167723 · Cited by 19
Tai, D. W.-M., Conroy, T., Lee, J. J. X., Chee, C. E., Hao, C., Wijaya, I., Aggarwal, S., Ueno, M., Jeung, H., Hashim, N. M., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105826 · Cited by 19
Roth, S., Apte, M. V., Balachandran, V. P., Biffi, G., Conroy, T., Cukierman, E., Dotan, E., Esposito, I., Grünwald, B. T., Klauß, M., et al. (2026) · Nature Reviews Disease Primers · doi:10.1038/s41572-026-00699-6 · Cited by 19
Novel systemic treatment approaches for metastatic pancreatic cancer
Dorman, K., Heinemann, V., Kobold, S., von Bergwelt‐Baildon, M., & Boeck, S. H. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2037552 · Cited by 19
New Approaches with Precision Medicine in Adult Brain Tumors
Leibetseder, A., Preusser, M., & Berghoff, A. S. (2022) · Cancers · doi:10.3390/cancers14030712 · Cited by 19
PSMA-Directed Imaging and Therapy of Salivary Gland Tumors: A Single-Center Retrospective Study
Civan, C., Kasper, S., Berliner, C., Costa, P. F., Grünwald, V., Pogorzelski, M., Schaarschmidt, B. M., Lang, S., Kersting, D., Nader, M., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264342 · Cited by 19
Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology
Capuozzo, M., Santorsola, M., Landi, L., Granata, V., Perri, F., Celotto, V., Gualillo, O., Nasti, G., & Ottaiano, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315124 · Cited by 19
Unk, M., Novaković, B. J., & Novaković, S. (2023) · Cancers · doi:10.3390/cancers15051498 · Cited by 19
Metadata
- Authors
- Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., van Tilburg, C. M., Nagasubramanian, R., Berlin, J. D., Federman, N., Mascarenhas, L., Geoerger, B., Dowlati, A., Pappo, A. S., Bielack, S., Doz, F., McDermott, R., Patel, J. D., Schilder, R. J., Tahara, M., Pfister, S. M., Witt, O., Ladanyi, M., Rudzinski, E. R., Nanda, S., Childs, B. H., Laetsch, T. W., Hyman, D. M., & Drilon, A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- Stanford Medicine (US)
- Massachusetts General Hospital (US)
- Seattle Children's Hospital (US)
- University of Copenhagen (DK)
- Vanderbilt University Medical Center (US)
- University of California, Los Angeles (US)
- University of Southern California (US)
- Université Paris-Saclay (FR)
- University Hospitals Cleveland Medical Center (US)
- St. Jude Children's Research Hospital (US)
- Olgahospital (DE)
- Université Paris Descartes (FR)
- Cancer Trials Ireland (IE)
- University of Chicago (US)
- Thomas Jefferson University (US)
- National Cancer Center Hospital East (JP)
- German Cancer Research Center (DE)
- Memorial Sloan Kettering Cancer Center (US)
- Bayer (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- Drilon, Alexander
- ORCID
- Hong, David S
- DuBois, Steven G
- Kummar, Shivaani
- Farago, Anna F
- Albert, Catherine M
- Rohrberg, Kristoffer S
- Nagasubramanian, Ramamoorthy
- Berlin, Jordan D
- Federman, Noah
- Mascarenhas, Leo
- Geoerger, Birgit
- Dowlati, Afshin
- Pappo, Alberto S
- Bielack, Stefan
- Doz, François
- McDermott, Ray
- Patel, Jyoti D
- Tahara, Makoto
- Pfister, Stefan M
- Witt, Olaf
- Ladanyi, Marc
- Rudzinski, Erin R
- Nanda, Shivani
- Childs, Barrett H
- Laetsch, Theodore W
- Hyman, David M
- Drilon, Alexander
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 21
- Issue
- 4
- Pages
- 531-540
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC7497841
- OpenAlex
- W3008107700
- Cited by
- 1,028
- References
- 25
- Citations by year
- 2026: 106 · 2025: 148 · 2024: 162 · 2023: 178 · 2022: 202 · 2021: 171 · 2020: 60
- FWCI
- 86.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Loxo Oncology
- Bayer Corporation
- Bayer Fund
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- larotrectinib, TRK inhibitors, objective response rate, long-term safety, adverse events, childhood cancer, adult cancer, metastatic cancer, pooled analysis of clinical trials, alanine aminotransferase elevation, neutropenia, anemia, complete response, dose-limiting toxicity
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Neoplasms, Proteins, Pyrazoles, Pyrimidines, Vesicular Transport Proteins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
